quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:41:53·28d
SECFiling
Cardiff Oncology Inc. logo

Amendment: SEC Form SCHEDULE 13G/A filed by Cardiff Oncology Inc.

CRDF· Cardiff Oncology Inc.
Health Care
Original source

Companies

  • CRDF
    Cardiff Oncology Inc.
    Health Care

Recent analyst ratings

  • Jan 5UpdateNoble Capital Markets$12.00
  • Jul 8UpdateLadenburg Thalmann$19.00
  • Jun 24UpdateJefferies$3.50
  • Sep 6UpdateCraig Hallum$8.00
  • Feb 28UpdateHC Wainwright & Co.$25.00
  • Jan 5UpdateWilliam Blair-

Related

  • SEC16h
    SEC Form DEFA14A filed by Cardiff Oncology Inc.
  • SEC16h
    SEC Form DEF 14A filed by Cardiff Oncology Inc.
  • PR2d
    Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
  • PR6d
    Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
  • INSIDER7d
    SEC Form 3 filed by new insider Muntner Joshua B
  • INSIDER7d
    Amendment: SEC Form 4 filed by Muntner Joshua B
  • INSIDER7d
    SEC Form 4 filed by Smeal Tod
  • INSIDER7d
    SEC Form 4 filed by Muntner Joshua B
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022